Caspofungin in the treatment of candidosis and aspergillosis

International Journal of Infectious Diseases

Volumn 7, Issue 2, 2003, Pages 94-101

  Maertens, Johan ^a   Boogaerts, Marc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACULEACIN A; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CILOFUNGIN; CYCLOSPORIN A; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; GLUCAN; ITRACONAZOLE; MULUNDOCANDIN; NUCLEOSIDE DERIVATIVE; PNEUMOCANDIN DERIVATIVE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE; WF 11899;

ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CELL WALL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHILIA; FEBRILE NEUTROPENIA; FUNGAL CELL; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; IN VITRO STUDY; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; LUNG INFILTRATE; MAMMAL; NEPHROTOXICITY; NONHUMAN; PHLEBITIS; PROTEINURIA; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 0037662910     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(03)90003-8     Document Type: Review

References (57)

1. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27:1138-1147.
2. Denning D. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
3. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-366.
4. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
5. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-1079.
6. Klont RR, Meis JFGM, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001; 7(suppl 2):32-37.
7. Von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62:341-347.
8. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97:1604-1610.
9. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15:139-147.
10. Hebart H, Löffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181:1713-1719.
11. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus study group. Medicine 2000; 79:250-260.
12. Maertens J, Theunissen K, Boogaerts M. Invasive aspergillosis: focus on new approaches and new therapeutic agents. Curr Med Chem-Anti-Infective Agents 2002; 1:65-81.
13. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219-225.
14. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32:686-693.
15. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently neutropenic patients. J Clin Oncol 2000; 18:2476-2483.
16. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis 2002; 35:896-897.
17. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002; 35:891-895.
18. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48:471-497.
19. Maertens J, Boogaerts M. Fungal cell wall inhibitors. Curr Pharmaceut Design 2000; 6:225-239.
20. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35:79-86.
21. Kurtz MB. New antifungal drug targets: a vision for the future. ASM News 1999; 64:31-39.
22. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998; 31:33-37.
23. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazoles and echinocandin agents. Diagn Microbiol Infect Dis 1999; 35:19-25.
24. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999; 18:302-304.
25. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950-2956.
26. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30:251-255.
27. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii [Abstract M-230]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:381.
28. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41:2333-2338.
29. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44:2310-2318.
30. Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45:1854-1859.
31. Kohler S, Wheat LJ, Connolly P. et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44:1850-1854.
32. Petraitis V, Petraitiene R, Kelaher A, et al. Antifungal activity and safety of caspofungin against experimental disseminated candidiasis in persistently neutropenic rabbits [Abstract M-188]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:371.
33. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45:3474-3481.
34. Powles MA, Liberator P, Anderson J, et al. Efficacy of MK0991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1985-1989.
35. Bartizal K, Motyl M, Hicks P, et al. In vitro susceptibility results and correlation with outcome: results from a randomized invasive candidiasis study of caspofungin versus amphotericin B [Abstract M-1240]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego Ca. Washington, DC: American Society for Microbiology, 2002:402.
36. Colombo AL, Perfect J, Bartizal K, et al. Geographic distribution and response rates for various Candida species: results from the multicenter randomized invasive candidiasis study of caspofungin versus amphotericin B [Abstract M-1526]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:413.
37. Gobernado E, Canton E, Peman J, et al. Multicenter susceptibility testing of Candida clinical isolates to caspofungin by three different methods [Abstract M1496]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:406.
38. Arikan S, Lozano-Chiu M, Paetznick V, Rex J. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46:245-247.
39. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-2332.
40. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2339-2344.
41. Groll AH, Gullick BM, Petraitiene R, et al. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 2001; 45:596-600.
42. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-745.
43. Stone JA, McCrea J, Wickersham P, et al. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen [Abstract 854]. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 2000:26.
44. Stone J, Migoya E, Li S, et al. Safety and pharmacokinetics of higher doses of caspofungin [Abstract A-1389]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:19.
45. Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000; 28:1274-1278.
46. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics of caspofungin in paediatric patients [Abstract M-896]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:395.
47. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-1535.
48. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized double-blind multicenter study of caspofungin versus amphotericin for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46:451-457.
49. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomised double-blind study of caspofungin and amphotericin B for invasive candidiasis. Am J Med 2002; 113:294-299.
50. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029.
51. Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles [Abstract 1103]. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 2000:371.
52. Maertens J, Hiemenz J, Raad I, et al. Efficacy of caspofungin as salvage therapy in invasive aspergillosis as compared to standard therapy in a historical control [Abstract]. In: llth European Congress of Clinical Microbiology and Infectious Diseases, Istanbul, 2001.
53. Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients [Abstract M-868]. In 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:388.
54. Rubin MA, Carroll KC, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34:1160.
55. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002; 34:1415-1417.
56. Douglas CM, Abruzzo G, Bowman JC, et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in neutropenic guinea pig model of disseminated aspergillosis [Abstract M-1819]. In: 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:416.
57. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies [Abstract M-1820]. In 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Ca. Washington, DC: American Society for Microbiology, 2002:416.